[21D1-21D1];[21E2-21E2];
A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
21D1;21E2
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(2L)BSC107.
The presence of P+PBac{XP5.WH5}BSC456 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d01181 to be Release 3 genomic coordinate 481002 on chromosome arm 2L. The Gene Disruption project determined the insertion site of P{XP}d01181 to be Release 3 genomic coordinate 481354 on arm 2L. This corresponds to 21C6 on the Release 3 genome map and 21D1 on the Release 5 genome map. The predicted position of PBac{WH}CG3639f01300 on the Release 5 map is 21E2. Consequently, the cytological breakpoints of Df(2L)BSC456 are predicted to be 21D1;21E2.